78.29
Globus Medical Inc stock is traded at $78.29, with a volume of 1.12M.
It is up +0.22% in the last 24 hours and down -3.95% over the past month.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
See More
Previous Close:
$78.12
Open:
$77.23
24h Volume:
1.12M
Relative Volume:
0.71
Market Cap:
$10.51B
Revenue:
$3.10B
Net Income/Loss:
$586.71M
P/E Ratio:
18.23
EPS:
4.2937
Net Cash Flow:
$605.57M
1W Performance:
-5.64%
1M Performance:
-3.95%
6M Performance:
-13.45%
1Y Performance:
+29.86%
Globus Medical Inc Stock (GMED) Company Profile
Name
Globus Medical Inc
Sector
Industry
Phone
610-930-1800
Address
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
GMED
Globus Medical Inc
|
78.29 | 11.50B | 3.10B | 586.71M | 605.57M | 4.2937 |
|
ABT
Abbott Laboratories
|
108.33 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
94.17 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
SYK
Stryker Corp
|
303.13 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
BSX
Boston Scientific Corp
|
47.80 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
89.90 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Needham | Hold → Buy |
| Jan-27-26 | Initiated | TD Cowen | Buy |
| Nov-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-07-25 | Upgrade | Truist | Hold → Buy |
| Oct-28-25 | Resumed | Stifel | Hold |
| May-27-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-10-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-20-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-18-24 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-19-23 | Upgrade | Stifel | Hold → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-13-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-10-23 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-10-23 | Downgrade | Loop Capital | Buy → Hold |
| Feb-10-23 | Downgrade | Needham | Buy → Hold |
| Feb-10-23 | Downgrade | Truist | Buy → Hold |
| Feb-10-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-28-22 | Initiated | Wells Fargo | Overweight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-13-21 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-29-21 | Initiated | Loop Capital | Buy |
| Feb-18-21 | Resumed | Needham | Buy |
| Dec-08-20 | Initiated | Citigroup | Buy |
| Oct-20-20 | Initiated | Stifel | Hold |
| Aug-06-20 | Reiterated | Needham | Buy |
| Aug-06-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-21-20 | Initiated | Northland Capital | Market Perform |
| Jul-06-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-08-20 | Reiterated | Needham | Buy |
| Mar-18-20 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Dec-12-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Aug-02-19 | Reiterated | Needham | Buy |
| May-24-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| May-03-19 | Reiterated | Needham | Buy |
| Feb-28-19 | Upgrade | UBS | Neutral → Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-02-18 | Reiterated | Needham | Buy |
| Jun-27-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-18 | Reiterated | Needham | Buy |
| Apr-04-18 | Upgrade | Needham | Hold → Buy |
View All
Globus Medical Inc Stock (GMED) Latest News
Philips Expands Women's Health Ultrasound Portfolio With New Transducer - Zacks Investment Research
Globus Medical Clears Excelsius3D for European Sales - mychesco.com
Globus Medical (GMED) Received CE Mark For Its Excelsius3D Imaging System - Yahoo Finance
Globus Medical Announces CE Mark for Excelsius3D™ Imaging System Excelsius3D™ – Intelligent 3-in-1 Imaging System Expands Excelsius™ Ecosystem in the European Union - Orthopedics This Week
Globus Medical Announces CE Mark for Excelsius3D™ Imaging System - Ortho Spine News
Globus Medical’s Excelsius3D imaging system receives CE mark - Yahoo Finance
Globus Medical receives CE mark for Excelsius3D imaging system By Investing.com - Investing.com South Africa
Globus Medical Inc (GMED) Stock Down 3.1% -- Now Undervalued? GF Score: 94/100 - GuruFocus
Globus Medical’s $840.5 Million War Chest — Robotics, Innovation & Expansion Converge! - Smartkarma
Globus Medical stock rises on EU approval for imaging system By Investing.com - Investing.com South Africa
Globus Medical Announces CE Mark for Excelsius3D Imaging System - Investing News Network
Globus Medical stock rises on EU approval for imaging system - Investing.com
Globus Medical Slides 3.1% Despite New Product Milestone as Investors Weigh Recent Growth Questions - Quiver Quantitative
Globus Medical Wins EU, UK Approval to Market Excelsius3D Imaging Platform - marketscreener.com
Globus Medical receives CE mark for Excelsius3D imaging system - Investing.com
Audubon’s Globus Medical Acquires Duke Spinout Higgs Boson Health - BioBuzz
3 Reasons Growth Investors Will Love Globus Medical (GMED) - Yahoo Finance
Globus Medical, Inc. (GMED) Investor Outlook: Analyzing a 24% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
M&A: Globus Medical Acquires Duke Incubator Higgs Boson Health to Expand Surgical Intelligence - hitconsultant.net
BMO Capital Maintains Globus Medical(GMED.US) With Buy Rating, Maintains Target Price $94 - Moomoo
Wall Street Analysts Believe Globus Medical (GMED) Could Rally 25.03%: Here's is How to Trade - Yahoo Finance
Is Globus Medical (GMED) A Bargain On Its Robotics And Margin Growth Story? - Yahoo Finance
Globus Medical acquires digital health firm Higgs Boson By Investing.com - Investing.com Nigeria
Globus Medical Acquires Higgs Boson Health to Expand Digital Healthcare and Surgical Intelligence Ecosystem - Quiver Quantitative
Globus Medical announces AI acquisition with a 95% good-outcomes goal at 10 years - Stock Titan
Globus Medical Announces Acquisition of Higgs Boson Health - globenewswire.com
Globus Medical, Inc. agreed to acquire Higgs Boson, Inc. - marketscreener.com
Globus Medical Inc (GMED) Stock Down 3.3% -- Now Undervalued? GF Score: 95/100 - GuruFocus
Globus Medical (GMED) Could Be 17% Undervalued On Its Robotics Growth Narrative - Sahm
Globus Medical (NYSE:GMED): A Decent Value Stock With Solid Fundamentals - ChartMill
Globus Medical (GMED) Stock Could Be Undervalued Following Margin Gains Update - Yahoo Finance
Globus Medical Inc (GMED) Stock Down 3.0% -- Now Undervalued? GF Score: 95/100 - GuruFocus
Globus Medical Director Stephen T. Zarrilli Executes Stock Options and Sells Shares on August 18, 2026 - Kalkine Media
Globus Medical Director Sold Shares Worth Over $2.1M - TradingView
Globus Medical (NYSE: GMED) director exercises options, sells 25,000 shares - Stock Titan
Globus Medical: The Dip Makes It Cheaper, Not Different (NYSE:GMED) - Seeking Alpha
Globus Medical: 7 Quarters Of Margin Expansion, Priced For None (NYSE:GMED) - Seeking Alpha
Globus Medical (NYSE: GMED) insider plans $2.2M sale - Stock Titan
Looking for a Growth Stock? 3 Reasons Why Globus Medical (GMED) is a Solid Choice - qz.com
Here is Why Growth Investors Should Buy Globus Medical (GMED) Now - Yahoo Finance
Is Revenue Growth Amid Margin Pressure Altering The Investment Case For Globus Medical (GMED)? - Sahm
Globus Medical (GMED) Stock Analysis: Navigating a 20% Potential Upside with Healthcare Innovation - DirectorsTalk Interviews
Assenagon Asset Management S.A. Sells 127,216 Shares of Globus Medical, Inc. $GMED - MarketBeat
Globus Medical (GMED) Institutional Ownership 2026 - MarketBeat
Globus Medical Inc (GMED) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Globus Medical (GMED) Stock Sees Modest Fair Value Cut As Analysts Trim Growth Views - Yahoo Finance
Is Globus Medical (GMED) A Bargain On Its Zacks Upgrade And Reaffirmed Guidance? - Yahoo Finance
Globus Medical, Inc. (GMED) Stock Forecasts - Yahoo Finance
Globus Medical (NYSE:GMED) Upgraded at Zacks Research - MarketBeat
Annex Advisory Services LLC Boosts Holdings in Globus Medical, Inc. $GMED - MarketBeat
Q2 2026 Globus Medical, Inc. Earnings Call Transcript - GuruFocus
Globus Medical Inc Stock (GMED) Financials Data
Revenue
Net Income
Cash Flow
EPS
Globus Medical Inc Stock (GMED) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ZARRILLI STEPHEN T | Director |
Aug 18 '26 |
Sale |
87.04 |
25,000 |
2,175,965 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):